Capricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority Review

Dow Jones

Mar 04, 2025

By Katherine Hamilton

The Food and Drug Administration has accepted Capricor Therapeutics' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review.

The FDA plans to take action on the application by Aug. 31, Capricor said Tuesday.

Shares rose 17% to $15.99 in pre-market trading Tuesday. They have nearly tripled in value over the past year.

Deramiocel is specifically being reviewed by the FDA to treat patients diagnosed with Duchenne muscular dystrophy cardiomyopathy.

If the San Diego company gets FDA marketing approval for deramiocel regarding the treatment of Duchenne muscular dystrophy by Sept. 30, 2026, it would be eligible to receive a priority review voucher based on its previous receipt of a rare pediatric disease designation.

The FDA grants priority review to medicine applications that, if approved, would provide significant improvements in the safety or effectiveness of the treatment of a serious condition.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 04, 2025 07:37 ET (12:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516443673"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516443673\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516443673?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516443673","market":"us","top_or_hot":-1,"title":"Capricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority Review","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  The Food and Drug Administration has accepted Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review. \n</p>\n<p>\n  The FDA plans to take action on the application by Aug. 31, Capricor said Tuesday. \n</p>\n<p>\n  Shares rose 17% to $15.99 in pre-market trading Tuesday. They have nearly tripled in value over the past year. \n</p>\n<p>\n  Deramiocel is specifically being reviewed by the FDA to treat patients diagnosed with Duchenne muscular dystrophy cardiomyopathy. \n</p>\n<p>\n  If the San Diego company gets FDA marketing approval for deramiocel regarding the treatment of Duchenne muscular dystrophy by Sept. 30, 2026, it would be eligible to receive a priority review voucher based on its previous receipt of a rare pediatric disease designation. \n</p>\n<p>\n  The FDA grants priority review to medicine applications that, if approved, would provide significant improvements in the safety or effectiveness of the treatment of a serious condition. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 07:37 ET (12:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-04 20:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  The Food and Drug Administration has accepted Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review. \n</p>\n<p>\n  The FDA plans to take action on the application by Aug. 31, Capricor said Tuesday. \n</p>\n<p>\n  Shares rose 17% to $15.99 in pre-market trading Tuesday. They have nearly tripled in value over the past year. \n</p>\n<p>\n  Deramiocel is specifically being reviewed by the FDA to treat patients diagnosed with Duchenne muscular dystrophy cardiomyopathy. \n</p>\n<p>\n  If the San Diego company gets FDA marketing approval for deramiocel regarding the treatment of Duchenne muscular dystrophy by Sept. 30, 2026, it would be eligible to receive a priority review voucher based on its previous receipt of a rare pediatric disease designation. \n</p>\n<p>\n  The FDA grants priority review to medicine applications that, if approved, would provide significant improvements in the safety or effectiveness of the treatment of a serious condition. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 07:37 ET (12:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAPR","symbol_name":"Capricor Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2516443673","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516443673","pubTimestamp":1741091820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The Food and Drug Administration has accepted Capricor Therapeutics' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review.The FDA plans to take action on the application by Aug. 31, Capricor said Tuesday.Shares rose 17% to $15.99 in pre-market trading Tuesday. They have nearly tripled in value over the past year.Deramiocel is specifically being reviewed by the FDA to treat patients diagnosed with Duchenne muscular dystrophy cardiomyopathy.If the San Diego company gets FDA marketing approval for deramiocel regarding the treatment of Duchenne muscular dystrophy by Sept. 30, 2026, it would be eligible to receive a priority review voucher based on its previous receipt of a rare pediatric disease designation.The FDA grants priority review to medicine applications that, if approved, would provide significant improvements in the safety or effectiveness of the treatment of a serious condition.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAPR":"Capricor Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Capricor Therapeutics针对肌营养不良患者的细胞疗法获得FDA优先审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":1},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  The Food and Drug Administration has accepted Capricor Therapeutics' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review. \n\n\n  The FDA plans to take action on the application by Aug. 31, Capricor said Tuesday. \n\n\n  Shares rose 17% to $15.99 in pre-market trading Tuesday. They have nearly tripled in value over the past year. \n\n\n  Deramiocel is specifically being reviewed by the FDA to treat patients diagnosed with Duchenne muscular dystrophy cardiomyopathy. \n\n\n  If the San Diego company gets FDA marketing approval for deramiocel regarding the treatment of Duchenne muscular dystrophy by Sept. 30, 2026, it would be eligible to receive a priority review voucher based on its previous receipt of a rare pediatric disease designation. \n\n\n  The FDA grants priority review to medicine applications that, if approved, would provide significant improvements in the safety or effectiveness of the treatment of a serious condition. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 07:37 ET (12:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}